BioCryst reports delay in flu program

BCRX was off $8 (53 percent) to $7.188 on Thursday on news that partner R.W. Johnson Pharmaceutical Research Institute, a subsidiary of Johnson & Johnson (JNJ), will not begin two clinical studies in ...